ALLOGENE THERAPEUTICS INC(NASDAQ:ALLO) stock News

ALLO Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Zacks Investment Research

All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy

2 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

2 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

2 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

2 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

2 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

2 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

2 months ago - By: Zacks Investment Research - Mentions: REGN HALO

REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research

2 months ago - By: Yahoo Finance - Mentions: IOVA UBS NSIT AMGN

Why Iovance Biotherapeutics Tumbled by Nearly 6% Today

2 months ago - By: Yahoo Finance - Mentions: CAVA TSHA TTWO AMAT ...

Cava: Rapid Growth but Some Concerns

2 months ago - By: Zacks Investment Research - Mentions: HALO KOD

Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus

2 months ago - By: Zacks Investment Research

Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

2 months ago - By: Benzinga

Allogene Therapeutics's Earnings Outlook

2 months ago - By: Zacks Investment Research - Mentions: HALO FATE

Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus

2 months ago - By: Zacks Investment Research - Mentions: EXEL EDIT

EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line

2 months ago - By: Zacks Investment Research - Mentions: AGEN ADPT ELEV

Allogene's Q1 Earnings In Line With Estimates, Sales Nil

2 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

2 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

2 months ago - By: Zacks Investment Research - Mentions: AZN EDIT

Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y

2 months ago - By: Benzinga - Mentions: ICMB IRIX KLC ONON ...

Earnings Scheduled For May 13, 2025

2 months ago - By: Zacks Investment Research - Mentions: RDY ALVO

RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up

2 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

2 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

3 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

3 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

3 months ago - By: Allogene Therapeutics, Inc.

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

3 months ago - By: Allogene Therapeutics, Inc.

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

ALLOGENE THERAPEUTICS INC (ALLO) Stock News

ALLO Latest News, Press Relases and Analysis